Agilent Technologies has launched a new immunoassay kit for the detection of SARS-CoV-2 antibodies. The kit represents Agilent's entry into the U.S. SARS-CoV-2 testing market, according to the firm.
The test is called Agilent Dako SARS-CoV-2 immunoglobulin G (IgG) Enzyme-Linked Immunosorbent Assay (ELISA), and it identifies IgG antibodies to SARS-CoV-2 in human serum or plasma.
The test has 98.9% sensitivity and 98.8% specificity, the company said.
